Determinants of malaria testing at health facilities: the case of Uganda.
Malaria
Malaria diagnostic practices
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
04 Dec 2021
04 Dec 2021
Historique:
received:
23
08
2021
accepted:
18
11
2021
entrez:
5
12
2021
pubmed:
6
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The World Health Organization (WHO) recommends prompt malaria diagnosis with either microscopy or malaria rapid diagnostic tests (RDTs) and treatment with an effective anti-malarial, as key interventions to control malaria. However, in sub-Saharan Africa, malaria diagnosis is still often influenced by clinical symptoms, with patients and care providers often interpreting all fevers as malaria. The Ministry of Health in Uganda defines suspected malaria cases as those with a fever. A target of conducting testing for at least 75% of those suspected to have malaria was established by the National Malaria Reduction Strategic Plan 2014-2020. This study investigated factors that affect malaria testing at health facilities in Uganda using data collected in March/April 2017 in a cross-sectional survey of health facilities from the 52 districts that are supported by the US President's Malaria Initiative (PMI). The study assessed health facility capacity to provide quality malaria care and treatment. Data were collected from all 1085 public and private health facilities in the 52 districts. Factors assessed included supportive supervision, availability of malaria management guidelines, laboratory infrastructure, and training health workers in the use of malaria rapid diagnostic test (RDT). Survey data were matched with routinely collected health facility malaria data obtained from the district health information system Version-2 (DHIS2). Associations between testing at least 75% of suspect malaria cases with several factors were examined using multivariate logistic regression. Key malaria commodities were widely available; 92% and 85% of the health facilities reported availability of RDTs and artemether-lumefantrine, respectively. Overall, 933 (86%) of the facilities tested over 75% of patients suspected to have malaria. Predictors of meeting the testing target were: supervision in the last 6 months (OR: 1.72, 95% CI 1.04-2.85) and a health facility having at least one health worker trained in the use of RDTs (OR: 1.62, 95% CI 1.04-2.55). The study findings underscore the need for malaria control programmes to provide regular supportive supervision to health facilities and train health workers in the use of RDTs.
Sections du résumé
BACKGROUND
BACKGROUND
The World Health Organization (WHO) recommends prompt malaria diagnosis with either microscopy or malaria rapid diagnostic tests (RDTs) and treatment with an effective anti-malarial, as key interventions to control malaria. However, in sub-Saharan Africa, malaria diagnosis is still often influenced by clinical symptoms, with patients and care providers often interpreting all fevers as malaria. The Ministry of Health in Uganda defines suspected malaria cases as those with a fever. A target of conducting testing for at least 75% of those suspected to have malaria was established by the National Malaria Reduction Strategic Plan 2014-2020.
METHODS
METHODS
This study investigated factors that affect malaria testing at health facilities in Uganda using data collected in March/April 2017 in a cross-sectional survey of health facilities from the 52 districts that are supported by the US President's Malaria Initiative (PMI). The study assessed health facility capacity to provide quality malaria care and treatment. Data were collected from all 1085 public and private health facilities in the 52 districts. Factors assessed included supportive supervision, availability of malaria management guidelines, laboratory infrastructure, and training health workers in the use of malaria rapid diagnostic test (RDT). Survey data were matched with routinely collected health facility malaria data obtained from the district health information system Version-2 (DHIS2). Associations between testing at least 75% of suspect malaria cases with several factors were examined using multivariate logistic regression.
RESULTS
RESULTS
Key malaria commodities were widely available; 92% and 85% of the health facilities reported availability of RDTs and artemether-lumefantrine, respectively. Overall, 933 (86%) of the facilities tested over 75% of patients suspected to have malaria. Predictors of meeting the testing target were: supervision in the last 6 months (OR: 1.72, 95% CI 1.04-2.85) and a health facility having at least one health worker trained in the use of RDTs (OR: 1.62, 95% CI 1.04-2.55).
CONCLUSION
CONCLUSIONS
The study findings underscore the need for malaria control programmes to provide regular supportive supervision to health facilities and train health workers in the use of RDTs.
Identifiants
pubmed: 34863172
doi: 10.1186/s12936-021-03992-9
pii: 10.1186/s12936-021-03992-9
pmc: PMC8645102
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
456Subventions
Organisme : US President's Malaria Initiative
ID : AID-617-C-16-00001
Informations de copyright
© 2021. The Author(s).
Références
Bull World Health Organ. 2008 Feb;86(2):101-10
pubmed: 18297164
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):203-18
pubmed: 18165494
Braz J Otorhinolaryngol. 2015 Jul-Aug;81(4):394-401
pubmed: 26145251
Malar J. 2016 Feb 24;15:112
pubmed: 26911252
Malar J. 2016 Jan 11;15:23
pubmed: 26754484
Malar J. 2016 Nov 14;15(1):555
pubmed: 27842555
BMC Health Serv Res. 2021 Sep 13;21(Suppl 1):512
pubmed: 34511080
Asian Pac J Trop Biomed. 2012 Apr;2(4):307-10
pubmed: 23569920
Malar J. 2014 Dec 08;13:482
pubmed: 25491041
Malar J. 2010 Jul 12;9:200
pubmed: 20624312
Hum Resour Health. 2013 Sep 05;11:43
pubmed: 24007354
Hum Resour Health. 2017 Sep 2;15(1):58
pubmed: 28865466
BMJ Glob Health. 2019 Sep 29;4(5):e001849
pubmed: 31637032
BMC Public Health. 2017 May 18;17(1):470
pubmed: 28521798
Glob Health Action. 2017 Aug;10(sup4):1345496
pubmed: 28820340
BMC Med Inform Decis Mak. 2014 May 13;14:40
pubmed: 24886567